Get started

Juno Therapeutics (United States)

Alternate names: Juno Therapeutics, Juno Therapeutics, Inc.
ROR: 02dq5dx40
OpenAlex ID: I4405280080
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
2020 · Jeremy S Abramson, M Lia Palomba, et al. · The Lancet · 2,572
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
2016 · Cameron J. Turtle, Laïla-Aïcha Hanafi, et al. · Journal of Clinical Investigation · 2,161
PDF
Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
2017 · Juliane Gust, Kevin A. Hay, et al. · Cancer Discovery · 1,448
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy
2017 · Kevin A. Hay, Laïla-Aïcha Hanafi, et al. · Blood · 1,206
PDF
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
2017 · Rebecca A. Gardner, Olivia Finney, et al. · Blood · 1,158
PDF
Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
2016 · Cameron J. Turtle, Laïla-Aïcha Hanafi, et al. · Science Translational Medicine · 1,031
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
2018 · Bianca D. Santomasso, Jae H. Park, et al. · Cancer Discovery · 974
An essential role for the IL-2 receptor in Treg cell function
2016 · Takatoshi Chinen, Arun K Kannan, et al. · Nature Immunology · 942
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2019 · Laurie H. Sehn, Alex F. Herrera, et al. · Journal of Clinical Oncology · 812
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib
2017 · Cameron J. Turtle, Kevin A. Hay, et al. · Journal of Clinical Oncology · 669
Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy
2017 · Joshua A. Hill, Daniel Li, et al. · Blood · 600
PDF
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy
2019 · Kevin A. Hay, Jordan Gauthier, et al. · Blood · 414
PDF
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
2019 · Eric L. Smith, Kim Harrington, et al. · Science Translational Medicine · 402
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells
2019 · Alexandre V. Hirayama, Jordan Gauthier, et al. · Blood · 368
PDF
CD19 CAR T cell product and disease attributes predict leukemia remission durability
2019 · Olivia C. Finney, Hannah Brakke, et al. · Journal of Clinical Investigation · 358
PDF
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure
2020 · Jordan Gauthier, Alexandre V. Hirayama, et al. · Blood · 336
PDF
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy
2019 · Rebecca A. Gardner, Francesco Ceppi, et al. · Blood · 285
PDF
Chimeric Antigen Receptor T Cell–Mediated Neurotoxicity in Nonhuman Primates
2018 · Agne Taraseviciute, Victor Tkachev, et al. · Cancer Discovery · 264
Fully human CD19-specific chimeric antigen receptors for T-cell therapy
2017 · D Sommermeyer, T Hill, et al. · Leukemia · 225
Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma
2017 · Jeremy S. Abramson, Brianne McGree, et al. · New England Journal of Medicine · 211
PDF
Glial injury in neurotoxicity after pediatric CD19‐directed chimeric antigen receptor T cell therapy
2019 · Juliane Gust, Olivia C. Finney, et al. · Annals of Neurology · 203
BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies
2020 · Ruitao Lin, Yanhong Zhou, et al. · JCO Precision Oncology · 176
Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.
2018 · Jeremy S. Abramson, Leo I. Gordon, et al. · Journal of Clinical Oncology · 169
Imaging CAR T cell therapy with PSMA-targeted positron emission tomography
2019 · Il Minn, David J. Huss, et al. · Science Advances · 140
Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials
2018 · Ying Yuan, Ruitao Lin, et al. · Clinical Cancer Research · 137
Works count: 188
Citation count: 57,290
Year
Topic
Type